Raymond James Reiterates Outperform Rating on Monopar Therapeutics (MNPR) following Q4 results
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated an Outperform rating and $123.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
